

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **ARL6IP1 RABBIT PAB**

货号: S217048

产品全名: ARL6IP1 兔多抗 基因符号 AIP1; ARMER; ARL6IP

UNIPROT ID: Q15041 (Gene Accession - BC010281)

背景: ARMER (apoptotic regulator in the membrane of the endoplasmic reticulum), also known as ADP-ribosylation-like factor 6-interacting protein 1 (ARL6IPI or AIPI), is a multi-pass membrane protein that belongs to the Ras superfamily. It is expressed in brain, thymus, lung, bone marrow and, to a lesser extent, in spleen, kidney and liver. ARMER is not found in the heart and is found predominantly in early myeloid progenitor cells localizing to the intracytoplasmic membranes. It interacts with ARL6, inhibits caspase-9 activity by inhibiting proteolysis of downstream substrates (including LEHD-AFC, vimentin and caspase-3) and is down-regulated during myeloid differentiation. ARMER may play a role in membrane trafficking, protein transport or cell signaling during hematopoietic maturation.

抗原: Fusion protein of human ARL6IP1

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 1000-2000

种属反应性: Rabbit


克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cancer


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human breast cancer tissue using 217048(ARL6IP1 Antibody) at a dilution of 1/20(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with the fusion protein and then with 217048(Anti-ARL6IPI Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffinembedded Human gastric cancer tissue using 217048(Anti-ARL6IPI



In comparision with the IHC on the left, the same paraffin-embedded Human gastric cancer tissue is first treated with fusion protein and



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010